Torrent Pharma and Reliance Life Sciences Partner to Market IBD Biosimilars

Torrent Pharma and Reliance Life Sciences Partner to Market IBD Biosimilars
Torrent Pharmaceuticals Ltd. has signed a licensing agreement with Reliance Life Sciences for the marketing of three biosimilar products in India. The two companies are planning to market the biosimilars adalimumab, a treatment for inflammatory bowel disease (IBD), rheumatoid arthritis and psoriasis, as well as rituximab and cetuximab, which are used in oncology. Adalimumab is considered to be one of the most preferred

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *